These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Some clinical experiences with the arylsulfonylureas in the management of diabetes mellitus. ERK V; HAAR H; MCGAVACK TH; SEEGERS W Metabolism; 1956 Nov; 5(6 Part 2):919-32. PubMed ID: 13378061 [No Abstract] [Full Text] [Related]
44. [Oral therapy of diabetes]. MELLINGHOFF CH Med Klin; 1956 Sep; 51(36):1497-502. PubMed ID: 13358558 [No Abstract] [Full Text] [Related]
45. Clinical experiences with carbutamide, an orally given hypoglycemic agent; preliminary report. RIDOLFO AS; KIRTLEY WR J Am Med Assoc; 1956 Apr; 160(15):1285-8. PubMed ID: 13306540 [No Abstract] [Full Text] [Related]
46. The use of orinase in diabetes. BEASER SB Metabolism; 1956 Nov; 5(6 Part 2):933-9. PubMed ID: 13378062 [No Abstract] [Full Text] [Related]
47. [Examination of steroids in therapy with N'-sulfanilyl-N2-N-butylcarbamid (nadisan)]. RAUSCH-STROOMANN JG; SAUER H Klin Wochenschr; 1956 Jul; 34(25-26):707-8. PubMed ID: 13347046 [No Abstract] [Full Text] [Related]
48. Metabolic studies with the arylsulfonylureas. KUHL WJ Metabolism; 1956 Nov; 5(6 Part 2):953-63. PubMed ID: 13378065 [No Abstract] [Full Text] [Related]
50. Sulfonylureas and diabetes mellitus. II. Preliminary studies of the mechanism of action. COX RW; HENLEY ED; WILLIAMS RH Diabetes; 1956; 5(5):366-77. PubMed ID: 13365476 [No Abstract] [Full Text] [Related]
51. [BZ 55 of D 860 as oral antidiabetic]. MEHNERT B; MEHNERT H Munch Med Wochenschr; 1956 Sep; 98(39):1325-8. PubMed ID: 13378442 [No Abstract] [Full Text] [Related]
52. [Indications and successes of peroral treatment of diabetes mellitus with a sulfonylurea derivative; report on 335 cases]. BERTRAM F; BENDFELDT E; OTTO H Dtsch Med Wochenschr; 1956 Feb; 81(8):274-8. PubMed ID: 13317595 [No Abstract] [Full Text] [Related]
53. Symposium on clinical and experimental effects of sulfonylureas in diabetes mellitus; editorial statement. DUNCAN GG; LEVINE R Metabolism; 1956 Nov; 5(6 Part 2):721-6. PubMed ID: 13378038 [No Abstract] [Full Text] [Related]
54. Hypoglycemic effects of 1-butyl-3-p-toluene sulfonylurea given orally in human diabetic subjects; a preliminary report. MILLER M; CRAIG JW Metabolism; 1956 Mar; 5(2):162-4. PubMed ID: 13296878 [No Abstract] [Full Text] [Related]
55. Hypoglycemic sulfonylureas in various types of experimental diabetes. BUSE JF; GORDON MF; LUKENS FD Diabetes; 1957; 6(1):7-12; discussion, 19-20. PubMed ID: 13397410 [No Abstract] [Full Text] [Related]
56. Clinical experience with carbutamide and tolbutamide. COHN C; HEINEMAN A; LEVINE R; WEINSTEIN M Metabolism; 1956 Nov; 5(6 Part 2):972-7. PubMed ID: 13378067 [No Abstract] [Full Text] [Related]
57. [Oral treatment of diabetes mellitus with D-860, a new hypoglycemic but not sulfonamidic drug; clinical study of 90 cases]. INTROZZI P; MARIGO S Prog Med (Napoli); 1956 Sep; 12(17):513-27. PubMed ID: 13379550 [No Abstract] [Full Text] [Related]
58. [Criteria for selection of diabetics to be treated with oral hypoglycemic drugs; test for sensitivity to sulfonylurea compounds]. ARDUINO F Med Cir Farm; 1957 May; (253):187-98. PubMed ID: 13450825 [No Abstract] [Full Text] [Related]
59. Clinical experience and experimental studies with tolbutamide. CRAIG JW; MILLER M Diabetes; 1957; 6(1):77-9; discussion, 85-90. PubMed ID: 13397433 [No Abstract] [Full Text] [Related]
60. Diabetes mellitus. BERNHARD H Indian J Med Sci; 1957 Feb; 11(2):59-63. PubMed ID: 13428303 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]